文献速递肝病

肝硬化患者菌血症的全球抗菌素耐药趋势:系统综述与Meta分析

Global Trends in Antimicrobial Resistance Among Cirrhosis Patients With Bacteremia: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-23

该系统综述与Meta分析纳入26项研究、5610例菌血症病例,评估肝硬化患者菌血症病原体的全球抗菌素耐药趋势。菌血症合并率为20%,76%为医院获得性;多重耐药感染占31%,亚洲与欧洲均为35%;产超广谱β-内酰胺酶大肠埃希菌全球合并比例为14%,亚洲为21%。作者指出抗菌素耐药模式存在地域差异,亟需区域特异性感染控制、抗生素管理和加强耐药监测。

要点

  • 肝硬化菌血症病例中76%为医院获得性,多重耐药感染合并比例为31%。
  • 多重耐药率亚洲35%与欧洲35%相近;产超广谱β-内酰胺酶大肠埃希菌亚洲21%高于全球14%。
  • 碳青霉烯类耐药肠杆菌目细菌占5%,作者呼吁区域特异性感染控制与耐药监测。

核心结论

  • 菌血症在肝硬化患者中构成显著全球负担,抗菌素耐药模式存在地理差异。
  • 作者认为亟需区域特异性感染控制、抗生素管理和加强抗菌素耐药监测。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA指南(PROSPERO注册号CRD42024539347)。
  • 检索PubMed、Embase、Web of Science和Scopus,截止2024年12月15日。
  • 共纳入26项研究、5610例菌血症病例,采用随机效应模型计算合并比例及95%CI,用I2统计量评估异质性。
  • 按地区、细菌种类和耐药类型进行亚组分析。

主要发现

  • 菌血症合并率为20%(95%CI,12%-33%),其中76%(95%CI,64%-86%)为医院获得性。
  • 大肠埃希菌占27%(95%CI,17%-39%),金黄色葡萄球菌占16%(95%CI,12%-20%)。
  • 多重耐药感染为31%(95%CI,19%-44%),亚洲35%(95%CI,22%-49%)与欧洲35%(95%CI,26%-45%)相近。
  • 耐甲氧西林金黄色葡萄球菌在亚洲为13%(95%CI,0%-38%),在欧洲为10%(95%CI,3%-20%)。
  • 产超广谱β-内酰胺酶大肠埃希菌全球合并比例为14%(95%CI,7%-22%),亚洲为21%(95%CI,12%-31%);碳青霉烯类耐药肠杆菌目细菌占5%(95%CI,1%-11%)。

关键数值与推荐

  • 菌血症合并率20%(95%CI,12%-33%),医院获得性占76%(95%CI,64%-86%)。
  • 大肠埃希菌27%(95%CI,17%-39%),金黄色葡萄球菌16%(95%CI,12%-20%)。
  • 多重耐药感染31%(95%CI,19%-44%);亚洲35%(95%CI,22%-49%),欧洲35%(95%CI,26%-45%)。
  • 耐甲氧西林金黄色葡萄球菌亚洲13%(95%CI,0%-38%),欧洲10%(95%CI,3%-20%)。
  • 产超广谱β-内酰胺酶大肠埃希菌全球14%(95%CI,7%-22%),亚洲21%(95%CI,12%-31%);碳青霉烯类耐药肠杆菌目细菌5%(95%CI,1%-11%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Bacteremia in cirrhosis can rapidly progress to sepsis and multiorgan failure, contributing to significant morbidity and mortality. This systematic review and meta-analysis assess global trends in antimicrobial resistance (AMR) among bacterial pathogens causing bacteremia in patients with cirrhosis. METHODS: We conducted a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO: CRD42024539347). Searches across PubMed, Embase, Web of Science, and Scopus were completed up to December 15, 2024. Pooled proportions and 95% confidence intervals (CIs) were calculated using random-effects models. Heterogeneity was assessed with the I2 statistic, and subgroup analyses were performed by region, bacterial species, and AMR type. RESULTS: Twenty-six studies, comprising 5610 bacteremia cases, were included. The pooled bacteremia rate was 20% (95% CI, 12%-33%), with 76% (95% CI, 64%-86%) classified as nosocomial. Escherichia coli and Staphylococcus aureus accounted for 27% (95% CI, 17%-39%) and 16% (95% CI, 12%-20%) of cases, respectively. Multidrug-resistant infections were reported in 31% (95% CI, 19%-44%), with comparable rates observed in Asia (35%; 95% CI, 22%-49%) and Europe (35%; 95% CI, 26%-45%). Methicillin-resistant S. aureus was reported in 13% (95% CI, 0%-38%) of cases in Asia and 10% (95% CI, 3%-20%) in Europe. The pooled global proportion of extended-spectrum beta-lactamase-producing E. coli was 14% (95% CI, 7%-22%), with a higher estimate in Asia (21%; 95% CI, 12%-31%). Carbapenem-resistant Enterobacteriaceae were identified in 5% (95% CI, 1%-11%) of cases. CONCLUSIONS: Bacteremia poses a significant global burden in cirrhosis, with geographic variability in AMR patterns. These findings highlight the urgent need for region-specific infection control, antibiotic stewardship, and enhanced AMR surveillance.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Paintsil EK, Adu-Asiamah CK, Kronsten VT, et al. Global Trends in Antimicrobial Resistance Among Cirrhosis Patients With Bacteremia: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2025. PMID: 40712712. doi:10.1016/j.cgh.2025.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。